Michael Moore Is a director of several private and public bioscience companies and was Founder Chairman of Mission (2012-2016) and of PsiOxus Therapeutics (2011-2015). An extensive academic research career, principally at the Paterson Institute for Cancer Research, Manchester, preceded his becoming Research Director and CSO of Xenova Group plc. Dr Moore was CEO of Piramed, acquired by Roche in 2008, and is a past chairman of Trillium Therapeutics Inc. and of Cancer Research UK’s drug discovery committee. He is currently Chairman of Chronos Therapeutics. Dr Moore holds PhD and DSc degrees from the University of Nottingham and is a Fellow of the Royal College of Pathologists.